Key statistics
On Friday, Idorsia Ltd (IDIA:SWX) closed at 2.35, -21.31% below its 52-week high of 2.98, set on Jul 29, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.38 |
---|---|
High | 2.38 |
Low | 2.32 |
Bid | 2.31 |
Offer | 2.38 |
Previous close | 2.36 |
Average volume | 1.12m |
---|---|
Shares outstanding | 226.14m |
Free float | 142.09m |
P/E (TTM) | -- |
Market cap | 530.29m CHF |
EPS (TTM) | -1.37 CHF |
Data delayed at least 15 minutes, as of Jul 11 2025 16:38 BST.
More ▼
- A factory in a lab: Idorsia's breakthrough synthetic glycan vaccine platform validated for the first time in humans
- Bondholders approve amended terms of the 2025 and 2028 convertible bonds
- Idorsia launches repurchase offer for its 2025 and 2028 convertible bonds
- Idorsia’s QUVIVIQ expands into China as Simcere receives NDA approval – Idorsia and Simcere update their licensing agreement
- Idorsia announces the appointment of Srishti Gupta, MD as CEO to ensure the long-term success of Idorsia
- Idorsia publishes invitations to bondholder meetings
- Shareholders vote in favor of all proposals by the Board at Idorsia’s Annual General Meeting 2025
- New funds secured – allowing the commercial ramp-up of QUVIVIQ to accelerate Idorsia’s path to profitability
- Idorsia issues invitation to the 2025 Annual General Meeting of Shareholders
- Idorsia announces financial results for the first quarter 2025 – QUVIVIQ taking off in Europe and TRYVIO REMS removal increases the value of this outstanding asset
More ▼